Zenas BioPharma (ZBIO), a clinical-stage biopharmaceutical company focused on developing transformative therapies for autoimmune diseases, has regulatory milestones lined up for this year.
The company's approach blends disciplined product acquisition with late-stage development, anchored by two potential franchise molecules: Obexelimab and Orelabrutinib.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com